• Product NameLurasidone hydrochloride
• Brief DescriptionInhibitors
• Purification99.48%
• Biological ActivityLurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.
• Target Name5-HT Receptor antagonist; Dopamine Receptor inhibitor; Norepinephrine inhibitor
• CAS No. 367514-88-3
• Calculated MW 529.14
• Formulation C28H36N4O2SHCl
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Nervous system
  SMILES:C1CC[C@H]([C@@H](C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)[C@H]6[C@@H]7CC[C@@H](C7)[C@H]6C5=O.Cl
  Pathways:GPCR/G Protein; Neuroscience
  Receptor:5-HT1A; 5-HT2A; 5-HT7; D2; Norepinephrine α2C
  Boling pt:
  Melting pt:
  Solubility:DMSO: 1 mg/mL (1.88 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Murai T, et al. Behav Brain Res. 2014 Mar 15;261:26-30.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting